Table 4.
Patient self-reported measures of health-related quality of life for individuals who switched from adalimumab RP to ABP 501 (RP-ABP 501 switchers)
| RP-ABP 501 switchers | |
|---|---|
| Patient-reported treatment satisfaction, n (%) | |
| n | 49 |
| Satisfied | 48 (98.0) |
| Dissatisfied | 1 (2.0) |
| EQ-5D-5L | |
| n | 48 |
| EQ VAS, mean (SD) | 86.4 (10.3) |
| n | 47 |
| EQ-5D-5L German tariff, mean (SD) | 0.96 (0.05) |
| EQ-5D-5L domain: mobility, n (%) | |
| I have no problems in walking about | 43 (91.5) |
| I have slight problems in walking about | 4 (8.5) |
| I have moderate problems in walking about | 0 (0.0) |
| I have severe problems in walking about | 0 (0.0) |
| I am unable to walk | 0 (0.0) |
| EQ-5D-5L domain: self-care, n (%) | |
| I have no problems washing or dressing myself | 45 (95.7) |
| I have slight problems washing or dressing myself | 2 (4.3) |
| I have moderate problems washing or dressing myself | 0 (0.0) |
| I have severe problems washing or dressing myself | 0 (0.0) |
| I am unable to wash or dress myself | 0 (0.0) |
| EQ-5D-5L domain: usual activities, n (%) | |
| I have no problems doing my usual activities | 38 (80.9) |
| I have slight problems doing my usual activities | 9 (19.1) |
| I have moderate problems doing my usual activities | 0 (0.0) |
| I have severe problems doing my usual activities | 0 (0.0) |
| I am unable to do my usual activities | 0 (0.0) |
| EQ-5D-5L domain: pain/discomfort, n (%) | |
| I have no pain or discomfort | 29 (61.7) |
| I have slight pain or discomfort | 18 (38.3) |
| I have moderate pain or discomfort | 0 (0.0) |
| I have severe pain or discomfort | 0 (0.0) |
| I have extreme pain or discomfort | 0 (0.0) |
| EQ-5D-5L domain: anxiety/depression, n (%) | |
| I am not anxious or depressed | 37 (78.7) |
| I am slightly anxious or depressed | 7 (14.9) |
| I am moderately anxious or depressed | 3 (6.4) |
| I am severely anxious or depressed | 0 (0.0) |
| I am extremely anxious or depressed | 0 (0.0) |
| SIBDQ | |
| Total score, n | 49 |
| Total score, mean (SD) | 58.8 (8.7) |
| Bowel symptoms, n | 49 |
| Mean (SD) | 5.7 (0.9) |
| Systemic symptoms, n | 49 |
| Mean (SD) | 6.0 (0.9) |
| Emotional function, n | 49 |
| Mean (SD) | 5.7 (1.1) |
| Social function, n | 49 |
| Mean (SD) | 6.2 (1.1) |
| WPAI | |
| Overall work impairmenta, n | 27 |
| Mean, % (SD) | 12.7 (19.6) |
| Absenteeisma, n | 29 |
| Mean, % (SD) | 9.3 (27.0) |
| Presenteeisma, n | 31 |
| Mean, % (SD) | 11.0 (15.4) |
| Activity impairment, n | 49 |
| Mean, % (SD) | 16.5 (20.3) |
ABP 501 adalimumab biosimilar, EQ-5D-5L EuroQol-5 Dimension-5 Level, EQ VAS EuroQol visual analogue scale, RP reference product, SD standard deviation, SIBDQ Short Inflammatory Bowel Disease Questionnaire, WPAI Work Productivity and Activity Impairment
aExcludes non-working patients